Patents Assigned to Azurity Pharmaceuticals, Inc.
  • Amlodipine formulations
    Patent number: 11918685
    Abstract: Provided herein are stable amlodipine liquid formulations. Also provided herein are methods of using amlodipine liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
    Type: Grant
    Filed: May 30, 2023
    Date of Patent: March 5, 2024
    Assignee: AZURITY PHARMACEUTICALS, INC.
    Inventors: Scott Brauer, Gerold L. Mosher
  • Compositions and kits for omeprazole suspension
    Patent number: 11911473
    Abstract: Disclosed herein are liquid diluents, formulations, and kits for preparing reconstituted suspensions of a proton pump inhibitor (e.g., omeprazole). The present disclosure also provides formulations for liquid diluents that do not have a tendency for gel formation following exposure to freeze-thaw cycles.
    Type: Grant
    Filed: March 30, 2023
    Date of Patent: February 27, 2024
    Assignee: AZURITY PHARMACEUTICALS, INC.
    Inventors: Zeus Pendon, Steven Dinh
  • Liquid nimodipine compositions
    Patent number: 11819497
    Abstract: Liquid compositions comprising nimodipine having improved nimodipine concentrations are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the liquid compositions of the present invention are also detailed herein.
    Type: Grant
    Filed: October 26, 2022
    Date of Patent: November 21, 2023
    Assignee: AZURITY PHARMACEUTICALS, INC.
    Inventor: Hugh Greg Thomas
  • Composition and method for proton pump inhibitor suspension
    Patent number: 11813253
    Abstract: Suspensions of pump inhibitors (PPIs) are disclosed. The suspension may include a PPI, a copolymer of ethylene oxide and propylene oxide; simethicone emulsion; Sodium Bicarbonate; and Sodium Citrate, USP (Dihydrate). The suspensions have desirable viscosities and enhanced stability.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: November 14, 2023
    Assignee: AZURITY PHARMACEUTICALS, INC.
    Inventors: Ken Fallin, Kaity Renaud, Peter Mione, Neal Muni, Anisa Gandhi
  • Non-aqueous liquid nimodipine compositions
    Patent number: 11806338
    Abstract: Non-aqueous liquid compositions comprising nimodipine having improved stability over aqueous compositions comprising nimodipine are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the non-aqueous liquid compositions of the present invention are also detailed herein.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: November 7, 2023
    Assignee: AZURITY PHARMACEUTICALS, INC.
    Inventor: Hugh Greg Thomas
  • Compositions and kits for omeprazole suspension
    Patent number: 11771686
    Abstract: Disclosed herein are liquid diluents, formulations, and kits for preparing reconstituted suspensions of a proton pump inhibitor (e.g., omeprazole). The present disclosure also provides formulations for liquid diluents that do not have a tendency for gel formation following exposure to freeze-thaw cycles.
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: October 3, 2023
    Assignee: AZURITY PHARMACEUTICALS, INC.
    Inventors: Zeus Pendon, Steven Dinh
  • COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUID
    Publication number: 20230301907
    Abstract: The invention relates to stable vancomycin hydrochloride powder for oral liquid formulations. Also provided herein are methods of using vancomycin oral liquid formulations for the treatment of certain diseases such as Clostridium difficile pseudomembranous colitis and Staphylococcal enterocolitis as well as kits and related products thereof.
    Type: Application
    Filed: September 28, 2022
    Publication date: September 28, 2023
    Applicant: Azurity Pharmaceuticals, Inc.
    Inventors: Indu Muni, Peter Mione, Anisa Gandhi, Cristina LeChiara
  • Liquid nimodipine compositions
    Patent number: 11759457
    Abstract: Liquid compositions comprising nimodipine having improved nimodipine concentrations are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the liquid compositions of the present invention are also detailed herein.
    Type: Grant
    Filed: October 26, 2022
    Date of Patent: September 19, 2023
    Assignee: AZURITY PHARMACEUTICALS, INC.
    Inventor: Hugh Greg Thomas
  • Amlodipine formulations
    Patent number: 11701326
    Abstract: Provided herein are stable amlodipine liquid formulations. Also provided herein are methods of using amlodipine liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: July 18, 2023
    Assignee: AZURITY PHARMACEUTICALS, INC.
    Inventors: Scott Brauer, Gerold L. Mosher
  • Composition and method for vancomycin oral liquid
    Patent number: 11638692
    Abstract: The invention relates to stable vancomycin hydrochloride powder for oral liquid formulations. Also provided herein are methods of using vancomycin oral liquid formulations for the treatment of certain diseases such as Clostridium difficile pseudomembranous colitis and Staphylococcal enterocolitis as well as kits and related products thereof.
    Type: Grant
    Filed: October 13, 2022
    Date of Patent: May 2, 2023
    Assignee: Azurity Pharmaceuticals, Inc.
    Inventors: Indu Muni, Peter Mione, Anisa Gandhi, Cristina LeChiara
  • Compositions and kits for Omeprazole suspension
    Patent number: 11633478
    Abstract: Disclosed herein are liquid diluents, formulations, and kits for preparing reconstituted suspensions of a proton pump inhibitor (e.g., omeprazole). The present disclosure also provides formulations for liquid diluents that do not have a tendency for gel formation following exposure to freeze-thaw cycles.
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: April 25, 2023
    Assignee: Azurity Pharmaceuticals, Inc.
    Inventors: Zeus Pendon, Steven Dinh
  • COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUID
    Publication number: 20230102830
    Abstract: The invention relates to stable vancomycin hydrochloride powder for oral liquid formulations. Also provided herein are methods of using vancomycin oral liquid formulations for the treatment of certain diseases such as Clostridium difficile pseudomembranous colitis and Staphylococcal enterocolitis as well as kits and related products thereof.
    Type: Application
    Filed: October 13, 2022
    Publication date: March 30, 2023
    Applicant: Azurity Pharmaceuticals, Inc.
    Inventors: Indu Muni, Peter Mione, Anisa Gandhi, Cristina LeChiara
  • Oral pharmaceutical composition comprising zonisamide and process of preparation thereof
    Patent number: 11529333
    Abstract: The present invention relates to the pharmaceutical composition comprising Zonisamide and one or more pharmaceutically acceptable excipients and also relates to the process for the preparation of the pharmaceutical composition comprising Zonisamide.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: December 20, 2022
    Assignee: AZURITY PHARMACEUTICALS, INC.
    Inventors: Swati Nagar, Sandip P. Mehta, Manish Umrethia, Jayanta Kumar Mandal, Sandeep Pal
  • Liquid nimodipine compositions
    Patent number: 11517563
    Abstract: Liquid compositions comprising nimodipine having improved nimodipine concentrations are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the liquid compositions of the present invention are also detailed herein.
    Type: Grant
    Filed: March 30, 2022
    Date of Patent: December 6, 2022
    Assignee: Azurity Pharmaceuticals, Inc.
    Inventor: Hugh Greg Thomas
  • Amlodipine formulations
    Patent number: 11484498
    Abstract: Provided herein are stable amlodipine liquid formulations. Also provided herein are methods of using amlodipine liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: November 1, 2022
    Assignee: AZURITY PHARMACEUTICALS, INC.
    Inventors: Scott Brauer, Gerold L. Mosher
  • Oral pharmaceutical composition comprising Zonisamide and process of preparation thereof
    Patent number: 11478456
    Abstract: The present invention relates to the pharmaceutical composition comprising Zonisamide and one or more pharmaceutically acceptable excipients and also relates to the process for the preparation of the pharmaceutical composition comprising Zonisamide.
    Type: Grant
    Filed: March 15, 2022
    Date of Patent: October 25, 2022
    Assignee: AZURITY PHARMACEUTICALS, INC.
    Inventors: Swati Nagar, Sandip P. Mehta, Manish Umrethia, Jayanta Kumar Mandal, Sandeep Pal
  • Amlodipine formulations
    Patent number: 11471409
    Abstract: Provided herein are stable amlodipine liquid formulations. Also provided herein are methods of using amlodipine liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: October 18, 2022
    Assignee: AZURITY PHARMACEUTICALS, INC.
    Inventors: Scott Brauer, Gerold L. Mosher
  • Suspensions and diluents for metronidazole and baclofen
    Patent number: 11446246
    Abstract: Suspensions of metronidazole or baclofen and/or salts or ester derivative thereof, such as metronidazole benzoate, are disclosed. The suspension my include metronidazole or baclofen, and/or a salt or ester derivative thereof a hydrocolloid stabilizer, simethicone emulsion, a buffer, such as sodium citrate, (dihydrate), a preservative, a thickening agent, a sweetener, and water.
    Type: Grant
    Filed: April 21, 2022
    Date of Patent: September 20, 2022
    Assignee: Azurity Pharmaceuticals, Inc.
    Inventors: Ken Fallin, Zeus Pendon, Priya Capila, Neal Muni
  • Amlodipine formulations
    Patent number: 11364230
    Abstract: Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
    Type: Grant
    Filed: March 5, 2021
    Date of Patent: June 21, 2022
    Assignee: Azurity Pharmaceuticals, Inc.
    Inventors: Scott Brauer, Gerold L. Mosher
  • Suspensions and diluents for metronidazole and baclofen
    Patent number: 11324696
    Abstract: Suspensions of metronidazole or baclofen and/or salts or ester derivative thereof, such as metronidazole benzoate, are disclosed. The suspension my include metronidazole or baclofen, and/or a salt or ester derivative thereof a hydrocolloid stabilizer, simethicone emulsion, a buffer, such as sodium citrate, (dihydrate), a preservative, a thickening agent, a sweetener, and water.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: May 10, 2022
    Assignee: AZURITY PHARMACEUTICALS, INC.
    Inventors: Ken Fallin, Zeus Pendon, Priya Capila, Neal Muni